Home>Topics>Stocks>Vertex Pharmaceuticals

Vertex Pharmaceuticals VRTX

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. Headlines
    1. The Biotech Sell Off Is Largely Indiscriminate And The Best Stocks Are Not Over-Valued

      Headlines

      Mon, 31 Mar 2014

      Amgen ( AMGN ) - 2% Biogen ( BIIB ) -14% Celgene ( CELG ) -14% Alexion ( ALXN ) -19% Intercept ( ICPT ) -25% Vertex ( VRTX ) -18% Regeneron ( REGN ) -11% Medivation ( MDVN ) -28% Pharmacyclics ( PCYC ) -31% FBIOX Top 10 Weighted Average -16

    2. All Or Nothing - Understanding Structured Notes And Options Tied To Binary Events

      Headlines

      Tue, 18 Mar 2014

      By Joseph Halpern : A recent structured note caught my attention because it a) offered great characteristics and b) was based on an underlying biotechnology stock. These characteristics suggest that note performance may be tied to an upcoming binary, highly volatile event Did investors pick up on

    3. Sovaldi's Terrific Launch

      Headlines

      Mon, 17 Mar 2014

      projected at $8 billion for 2014. RBC analyst Michael Yee notes, Sovaldi's weekly total prescriptions are tracking 114 percent higher in its first full quarter of launch than what Incivek, Vertex's ( VRTX ) Hep C drug did. Complete Story »

    4. New Morningstar Analyst Report for Vertex Pharmaceuticals

      Stock Reports

      Thu, 30 Jan 2014

      willing to sell material amounts of stock rather than maintain their shareholdings as long-term investors. Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. The firm's lead drug

    5. How Did Facebook End Up in the S&P 500?

      Headlines

      Tue, 17 Dec 2013

      Michael Kors Holdings KORS, Delta Air Lines DAL, News Corp NWSA, oil-services company Transocean RIG, and Vertex Pharmaceuticals VRTX . Meanwhile, those leaving the index included Dell, Sprint S, J.C. Penney JCP, Dean Foods DF, and

    6. ClearBridge Fund Prepared for Extended Rally

      Video Reports

      Fri, 11 Oct 2013

      new oral multiple sclerosis compound. [TICKER:AMGN] Amgen as well, which recently announced an acquisition of [TICKER: VRTX ] Onyx Pharmaceuticals, has been strong from an earnings perspective and a stock perspective. And a name like Vertex, which

      VRTX found at 1:09

      oral multiple sclerosis compound. [TICKER:AMGN] Amgen as well, which recently announced an acquisition of [TICKER: VRTX ] Onyx Pharmaceuticals, has been strong from an earnings perspective and a stock perspective. And a name like Vertex, which has been a
    7. Gilead Sciences Carving Out a Wider Moat

      Headlines

      Thu, 8 Aug 2013

      weeks of therapy, with few side effects. For perspective, the current standard of care (with drugs like Vertex Pharmaceuticals ' VRTX Incivek) results in cure rates of around 70% for most previously untreated patients, treatment typically

    8. Vertex's Kalydeco Sees Strong Sales and Clinical Data, In Line With Our Expectations

      Commentary

      Mon, 29 Jul 2013

      Vertex VRTX reported second-quarter results that were in line with our expectations, and we're not making any changes to our $89-per

    9. 10 High-Conviction Purchases by Our Ultimate Stock Pickers

      Headlines

      Tue, 21 May 2013

      04 Medium 6,901 2 Cigna CI 2 None 67.90 1.19 High 19,529 2 St Jude STJ 3 Wide 47.00 0.96 Medium 13,369 2 Vertex VRTX 3 None 79.49 0.89 High 17,961 2 Pioneer PXD 1 Narrow 142.25 1.50 Medium 19,943 1 Devon DVN 5 Narrow 58.79 0.59

    10. More on Vertex Pharmaceuticals ( VRTX ): Q1 beats on both EPS and revenue, but net profit swung to a loss on a 25% drop in total sales as fewer patients initiated treatment - leading to a 42% drop in ...

      Headlines

      Tue, 30 Apr 2013

      More on Vertex Pharmaceuticals ( VRTX ): Q1 beats on both EPS and revenue, but net profit swung to a loss on a 25% drop in total sales as fewer patients initiated

    « Prev12345Next »
    Content Partners